Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibandronate IV vs PO for Malignant Bone Disease Pain
NCT02561039Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2006
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ibandronate in malignant bone neoplasm (2 arms), sponsored by Roche. Primary endpoints: Response rate according to reduction in BPI most acute pain score at Month 4 and Change in Karnofsky Performance Index at Month 4. Started Dec 2006; status: completed.
02
Drugs
ibandronate
03
Conditions
malignant bone neoplasm
Beyond the preview
Go deeper on NCT02561039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02561039.